SCHEMBL4428377

SCHEMBL4428377

O=C(OCc1ccc(F)cc1)c1ccc(OCc2ccc(F)cc2)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.55
NR4A2 P43354 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAOB P27338 4/20 0.48
PARP10 Q53GL7 1/20 0.48
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
RXRG P48443 1/20 0.44
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP12 P39900 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.44
PPARA Q07869 1/20 0.44
PARP1 P09874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4435052 0.91 RXRA (0.55) MAPTMAOBRXRARXRBRXRG
SCHEMBL8512033 0.89 SLC6A2 (0.57) MAPTKMT2ALMNAMRGPRX4
SCHEMBL4422888 0.87 RXRA (0.58) MAOBRXRARXRBRXRGMMP1
SCHEMBL4428716 0.85 NR4A2 (0.63) NR4A2LMNAHTTRXRARXRB
SCHEMBL4425326 0.85 KDM4E (0.59) MAPTNR4A2MAOBPARP10MMP1
SCHEMBL20463320 0.84 MAOB (0.64) NR4A2MEN1KMT2AMAOBPARP10
SCHEMBL22386719 0.81 MAOB (0.49) NR4A2MAOBPARP10LMNAHTT
SCHEMBL22386724 0.81 MAOB (0.49) NR4A2MAOBPARP10LMNAHTT
SCHEMBL5335214 0.79 MAPT (0.63) MAPTNR4A2MEN1KMT2AMAOB
SCHEMBL4552962 0.78 BRD4 (0.58) MEN1KMT2AMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515926-B1 FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA HOFFMANN LA ROCHE (CH) 2009-04-08 EP disclosed
CN-1274669-C Fluorobenzamides suitable for the treatment of alzheimer's disease or senile dementia HOFFMANN LA ROCHE (CH) 2006-09-13 CN disclosed
US-6951884-B2 Fluorobenzamides and uses thereof HOFFMANN-LA ROCHE INC. (US) 2005-10-04 US disclosed
CN-1659135-A Fluorobenzamides suitable for the treatment of alzheimer's disease or senile dementia HOFFMANN LA ROCHE (CH) 2005-08-24 CN disclosed
EP-1515926-A2 FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA F.HOFFMANN-LA ROCHE AG (CH) 2005-03-23 EP disclosed
US-20030236304-A1 Fluorobenzamides and uses thereof F. HOFFMANN-LA ROCHE AG (CH) 2003-12-25 US disclosed
WO-2003106380-A2 FLUOROBENZAMIDES F.HOFFMANN-LA ROCHE AG (CH) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236304-A1 Fluorobenzamides and uses thereof MAOB, MAOA, BCHE MAPT 360/4885NR4A2 1698/4885MEN1 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.